The DOI matches its Crossref record.
Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia [published erratum appears in Blood 1992 Aug 1;80(3):855]
Open accessAbstract
Although all-trans retinoic acid (RA) induces complete remission in a high proportion of patients with acute promyelocytic leukemia (APL), all groups have described clinical relapses despite continued RA treatment. This finding suggests that resistance to the cytodifferentiating effects of the retinoid had been acquired. To investigate potential mechanisms of clinical resistance to RA, we serially evaluated the clinical pharmacology of the drug in APL patients treated with this agent. Leukemic cells from patients relapsing from RA treatment were cultured in the presence of RA and examined for evidence of morphologic maturation. We also studied messenger RNA expression of the newly described gene product of the (15;17) translocation in APL, PML/RA receptor-alpha (PML/RAR-alpha). Serial pharmacokinetic studies showed that continuous daily RA treatment was associated with a marked decrease in plasma drug concentrations at the time of relapse compared with the initial day of therapy. Doubling the RA dose in six patients failed to reinduce response at the time of relapse and also failed to significantly augment plasma RA concentrations. However, leukemic cells obtained at the time of relapse from four patients retained in vitro sensitivity to the differentiating activity of RA (10(-6) mol/L). No change was observed in the pattern of PML/RAR-alpha expression assessed by Northern blot analysis at the time of relapse compared with pretreatment in two patients who were tested. These results indicate that clinical relapse and “resistance” to continuous treatment with all- trans RA in APL is associated with progressive reduction of plasma concentrations, potentially to levels below those that sustain differentiation of leukemic cells in vivo. Long-term success of this treatment will require the development of strategies that circumvent this pharmacologic phenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, it induces undesirable side effects (congenital malformations40 as well as mucocutaneous dryness, headache, and hypertriglyceridemia41) when administered at high concentrations.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [41]
In the citing paper
“In vivo tests showed that rats49 or human patients70 treated with ATRA-containing liposomes by intravenous administration had no decrease in plasma ATRA levels while animals/humans treated with oral formulation of ATRA (nonliposomal) had a significant decrease in plasma ATRA levels41,49.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [41]
In the citing paper
“Follow-up studies indicated that resistance was due to the decrease of ATRA concentration in the plasma, and thus the inability of the drug to differentiate leukemic cells41.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 2
- Brazzell RK, Colburn WA: Pharmacokinetics of the retin- oids isotretinoin and etretinate: A comparative review. J Am Acad Dermatol6:643, 1982
- Francis PA, Riggs JR, Muindi JR, Kris MG, Young CW, Warrell RP Jr: Modulation of all-trans retinoic acid (RA) pharma- cokinetics by a cytochrome P-450 enzyme system inhibitor. Proc Am Soc Clin Oncol (in press)
Cited by
Sorted by citations
Items 201–300 of 319
Li, S., Barua, A. B., & Huselton, C. A. (1996) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(96)00108-9 · Cited by 12
Acute Promyelocytic Leukemia: New Insights into Diagnosis and Therapy
Frankel, S. R. (1993) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30260-0 · Cited by 12
Self-citationWarrell, R. (1993) · The Lancet · doi:10.1016/0140-6736(93)92611-v · Cited by 12
Self-citationKvestad, H., Evensen, L., Lorens, J. B., et al. (2014) · Leukemia Research and Treatment · doi:10.1155/2014/143479 · Cited by 11
Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort
Thompson, G. R., Krois, C. R., Affolter, V. K., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01384-18 · Cited by 11
Pharmacokinetics and Pharmacogenetics of 13-cis-Retinoic Acid in the Treatment of Neuroblastoma
Veal, G. J., Rowbotham, S. E., & Boddy, A. V. (2007) · Therapies · doi:10.2515/therapie:2007020 · Cited by 11
1 Recent Advances in the Chemistry and Biology of Retinoids
Gale, J. B. (1993) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70374-6 · Cited by 11
Design and synthesis of (E)-4-((3-ethyl-2,4,4-trimethylcyclohex-2-enylidene)methyl)benzoic acid
Das, B. C., & Kabalka, G. W. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.05.136 · Cited by 11
Takahashi, N., Iwahori, A., Kawai, K., et al. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0922 · Cited by 11
Caviglioli, G., Parodi, B., Cafaggi, S., et al. (1994) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049409042645 · Cited by 11
Ikezoe, T., Daar, E. S., Hisatake, J., et al. (2000) · Blood · doi:10.1182/blood.v96.10.3553.h8003553_3553_3559 · Cited by 11
Thanh, H., Lý, B. T. K., Vũ, H. A., Sato, Y., Dung, P. C., & Xinh, P. T. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3203 · Cited by 10
Development and Challenges of Synthetic Retinoid Formulations in Cancer
Assi, S., Hajj, H. E., Hayar, B., Pisano, C., Saad, W., & Darwiche, N. (2022) · Current Drug Delivery · doi:10.2174/1567201819666220810094708 · Cited by 10
A phase 1 study of tazarotene in adults with advanced cancer
Jones, P. H., Burnett, R. D., Fainaru, I., Nadolny, P., Walker, P., Yu, Z., Tang-Liu, D. D.-S., Ganesan, T. S., Talbot, D. C., Harris, A. L., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601169 · Cited by 10
A Retinoic Acid β2-Receptor Agonist Exerts Cardioprotective Effects
Marino, A., Sakamoto, T., Tang, X., Gudas, L. J., & Levi, R. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250605 · Cited by 10
RAR-Selective Ligands: Receptor Subtype and Function Selectivity
Beard, R. L., & Chandraratna, R. A. S. (1999) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58483-1_6 · Cited by 10
Damiens, E. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_19 · Cited by 10
Thiruvengadam, R., Atiba, J. O., & Azawi, S. (1996) · Investigational New Drugs · doi:10.1007/bf00180817 · Cited by 10
Takeshita, A., Shigeno, K., Shinjo, K., et al. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099336 · Cited by 10
The Maturation of Differentiation Therapy
Cheson, B. D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208063270612 · Cited by 10
Stein, E. M., de Botton, S., Cluzeau, T., Pigneux, A., Liesveld, J. L., Cook, R. J., Rousselot, P. H., Rizzieri, D. A., Braun, T., Roboz, G. J., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2243356 · Cited by 9
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα
Qian, Z., Lin, W., Cai, X., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2299288 · Cited by 9
Transcription therapy for acute promyelocytic leukaemia
Douer, D. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.2.329 · Cited by 9
Karpavičienė, I., Valiulienė, G., Raškevičius, V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.012 · Cited by 9
Hirano, T., Kizaki, M., Kato, K., et al. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00052-8 · Cited by 9
Parkinson, D., & Smith, M. A. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-338 · Cited by 9
Zhang, L., Yan, Y., Zhu, D., Yang, W., Wang, W., Hu, Y., Yang, B., & He, Q. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9512-5 · Cited by 8
Pathogenetic Role of the PML/RARα Fusion Protein in Acute Promyelocytic Leukemia
Grignani, F., & Pelicci, P. G. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-85232-9_27 · Cited by 8
Koshiishi, C., Kanazawa, T., Vangrevelinghe, E., Honda, T., & Hatakeyama, S. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02849 · Cited by 8
Expression of SMRTβ promotes ligand-induced activation of mutated and wild-type retinoid receptors
Côté, S., McNamara, S., Brambilla, D., Bianchini, A., Rizzo, G., Rincon, S. V. D., Grignani, F., Nervi, C., & Miller, W. H. (2004) · Blood · doi:10.1182/blood-2003-10-3583 · Cited by 8
Self-citation6 Treatment of acute promyelocytic leukaemia
Fenaux, P., & Degos, L. (1996) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(96)80039-4 · Cited by 8
The Polymerase Chain Reaction: Its use in the Molecular Characterization and Diagnosis of Cancers
Kawasaki, E. S. (1992) · Cancer Investigation · doi:10.3109/07357909209024799 · Cited by 8
New strategies for the treatment of acute promyelocytic leukaemia
Mandelli, F. (1997) · Journal of Internal Medicine · doi:10.1111/joim.1997.242.s740.23 · Cited by 8
Imaizumi, M., Suzuki, H., Yoshinari, M., et al. (1998) · Blood · doi:10.1182/blood.v92.2.374.414a40_374_382 · Cited by 8
Minó, A., Lopez, F., Barbaro, R., et al. (2024) · Biomimetics · doi:10.3390/biomimetics9050257 · Cited by 7
Novotná, E., Morell, A., Büküm, N., Hofman, J., Danielisová, P., & Wsól, V. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02818-y · Cited by 7
Gonçalves, A., Rocha, F. A., & Estevinho, B. N. (2022) · Foods · doi:10.3390/foods11162533 · Cited by 7
Subacute toxicity of all‐trans‐retinoic acid loaded biodegradable microspheres in rats
Choi, Y., Lee, C., Park, K., et al. (2003) · Drug Development Research · doi:10.1002/ddr.10283 · Cited by 7
Mulvihill, M. J., Kan, J. L. C., Cooke, A. R., Bhagwat, S. S., Beck, P., Bittner, M., Cesario, C., Keane, D. M., Lazarescu, V., Nigro, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.020 · Cited by 7
Improved Homology Model of the Human all-trans Retinoic Acid Metabolizing Enzyme CYP26A1
Awadalla, M. K. A., Alshammari, T. M., Eriksson, L. A., & Méndez, P. S. (2016) · Molecules · doi:10.3390/molecules21030351 · Cited by 7
Costantini, L., Molinari, R., Farinon, B., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082494 · Cited by 7
Nair, R., Nair, C. N., & Advani, S. H. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809058394 · Cited by 7
Current approaches to acute promyelocytic leukemia
Frankel, S. R., & Powell, B. L. (2007) · Springer eBooks · doi:10.1007/978-0-585-38571-6_5 · Cited by 7
Self-citationXia, H., Cheng, Y., Xu, Y., et al. (2015) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502015000300006 · Cited by 6
Wolf, G., & Smas, C. M. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2000.tb01865.x · Cited by 6
Takahashi, N., Fukui, T., Iwahori, A., et al. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4254 · Cited by 6
Therapy of Acute Promyelocytic Leukemia
Soignet, S. L., & Maslak, P. G. (2004) · Advances in pharmacology · doi:10.1016/s1054-3589(04)51002-5 · Cited by 6
Toxicity of tretinoin in acute promyelocytic leukaemia
de Lacerda, J. F., Schmitt, K., Schwarz, R., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91203-3 · Cited by 6
Bilip, M., Shah, S. R., Mathiyalakan, M., et al. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2019.1710157 · Cited by 5
Tamibarotene for the treatment of acute promyelocytic leukemia
Takeshita, A., Shinagawa, K., Adachi, M., Ono, T., Kiguchi, T., & Naoe, T. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.943733 · Cited by 5
Chen, Z., Tao, R.-F., & Xue-min, X. (1992) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199209051003 · Cited by 5
Repeated Treatment Protocols for Melasma and Acquired Dermal Melanocytosis
Yoshimura, K., D, K. S. M., Aiba‐Kojima, E., Matsumoto, D., Machino, C., Nagase, T., Gonda, K., & Koshima, I. (2006) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2006.032074.x · Cited by 38
Action of exogenous differentiating agents on gene expression in cancer cells
Lea, M. A. (1992) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(92)90090-d · Cited by 5
Mansouri, S. E., Tod, M., Leclercq, M., et al. (1994) · Analytica Chimica Acta · doi:10.1016/0003-2670(94)85029-1 · Cited by 5
all‐trans Retinoic Acid: a Dose‐Seeking Study in Solid Tumors
Pitot, H. C., Rubin, J., Kovach, J. S., et al. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb26185.x · Cited by 4
Liu, X., Yin, W., Widjaya, A. S., et al. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.07.003 · Cited by 4
Resistance to Differentiation Therapy
Özpolat, B. (2009) · Springer eBooks · doi:10.1007/978-0-387-89445-4_10 · Cited by 4
Nadin, L., & Murray, M. T. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703579 · Cited by 4
Kim, K. J., & Byun, Y. (1999) · Biotechnology and Bioprocess Engineering · doi:10.1007/bf02931932 · Cited by 4
CAMAGNA, A., Testa, U., Masciulli, R., et al. (1998) · Medical Hypotheses · doi:10.1016/s0306-9877(98)90025-1 · Cited by 4
The combined differentiating effect of retinoic acid and vincristine on acute promyelocytic leukemia
Leung, M., & Wong, K.-F. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00090-2 · Cited by 4
Wiernik, P. H., Gallagher, R. E., & Tallman, M. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_23 · Cited by 5
Westarp, M. E., Westarp, M. P., Bollag, W. B., et al. (1994) · Cancer Treatment An Update · doi:10.1007/978-2-8178-0765-2_126 · Cited by 4
Gonçalves, A., Viegas, O., Faria, M. Â., Ferreira, I. M. P. L. V. O., Rocha, F. A., & Estevinho, B. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128991 · Cited by 3
Differentiation Induction in Leukemia and Lymphoma
de Vos, S., & Koeffler, H. P. (2006) · Elsevier eBooks · doi:10.1016/b978-012088393-6/50083-x · Cited by 3
Role of Cytochrome P450 in Prostate Cancer and its Therapy
Kaushik, R., Khan, S., Sharma, M., Hemalatha, S., Mueed, Z., & Poddar, N. K. (2020) · Current Enzyme Inhibition · doi:10.2174/1573408016666200218122044 · Cited by 3
Murray, M. T., & Butler, A. M. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00076-3 · Cited by 3
KN-62 analogues as potent differentiating agents of HL-60 cells
Schuler, A. D., Si, J., Mueller, L., et al. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.022 · Cited by 3
Molecular events as targets of anticancer drug therapy
Aszalós, A., & Eckhardt, S. (1997) · Pathology & Oncology Research · doi:10.1007/bf02907812 · Cited by 3
Retinoid receptors and acute promyelocytic leukaemia
Trayner, I. D., & Farzaneh, F. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90469-v · Cited by 3
Côté, S., Zhou, D.-C., Bianchini, A., et al. (2000) · Blood · doi:10.1182/blood.v96.9.3200.h8003200_3200_3208 · Cited by 3
Self-citationRetinoids and Differentiation of Normal and Malignant Hematopoietic Cells
Agadir, A., & Chomienne, C. (1999) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58483-1_9 · Cited by 3
Specific cell-signal targets for cancer chemotherapy
Aszalós, A. (2002) · Archives of Pharmacal Research · doi:10.1007/bf02975254 · Cited by 2
Koh, L. P., Goh, Y. T., Teoh, G., et al. (2001) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v30n4p401 · Cited by 2
Cod Liver Oil, but Not Retinoic Acid, Treatment Restores Bone Thickness in a Vitamin A-Deficient Rat
Baybutt, R. C., Standard, J., Dim, D. C., Quinn, T., Hamdan, H., Lin, D., Kunz, K., Bomstein, Z. S., Estorge, B. J., Herndon, B., et al. (2022) · Nutrients · doi:10.3390/nu14030486 · Cited by 3
Wang, H., Zheng, X., Behm, F. G., et al. (2000) · Blood · doi:10.1182/blood.v96.10.3529.h8003529_3529_3536 · Cited by 2
Liposome-Mediated Delivery of Retinoids
Mehta, K., Estey, E. H., & Lopez‐Berestein, G. (1998) · Springer eBooks · doi:10.1007/978-1-4899-0127-9_9 · Cited by 2
Gueddari, N., Madoulet, C., Lefèbvre, P., et al. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00019-9 · Cited by 2
Clinical Pharmacology of the Retinoids
Pastorino, U., Warrell, R. P., & Formelli, F. (1995) · Springer eBooks · doi:10.1007/978-3-642-79706-4_5 · Cited by 2
Self-citationPharmacokinetics and Metabolism of Low-Dose ATRA in Children — First Observations
Lanvers, C., Wagner, A., Dübbers, A., et al. (1998) · Hämatologie und Bluttransfusion · doi:10.1007/978-3-642-71960-8_76 · Cited by 2
Clinical and Molecular Advances in Acute Promyelocytic Leukaemia
de Thé, H., Degos, L., & Warrell, R. P. (1995) · Springer eBooks · doi:10.1007/978-3-642-79706-4_7 · Cited by 2
Self-citationAlghwyeen, W., Mohamed, S. F., Hashim, A. S., Aboali, A. A., Alahdab, G. M., & Salloum, O. H. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02036-5 · Cited by 1
Doustmihan, A., Jaymand, M., Fathi, M., & Jahanban‐Esfahlan, R. (2025) · Medical Oncology · doi:10.1007/s12032-025-03206-1 · Cited by 1
Li, W., Zhou, S., Liu, J., Luo, L., Zhang, L., Wang, J., Sun, Y., Gan, S., Hu, Y., Yang, H., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf267 · Cited by 1
PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response
de Thé, H., Zhu, J., Nasr, R., Ablain, J., & Lallemand-Breitenbach, V. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_23 · Cited by 1
Hu, L., Lv, J., Zhuo, W., et al. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12591 · Cited by 1
Retinoids for the Treatment of Glioblastoma
Das, A., Banik, N. L., & Ray, S. K. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_13 · Cited by 1
Conazoles and Cancer: A Review
Nesnow, S. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624059-00280 · Cited by 2
Wiernik, P. H., Gallagher, R. E., & Tallman, M. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_21 · Cited by 1
Retinoic Acid in Acute Myeloid Leukemias
de Thé, H., & Fenaux, P. (2015) · Wiley eBooks · doi:10.1002/9781118628003.ch25 · Cited by 1
Molecular Biology of Acute Promyelocytic Leukemia
Grignani, F., & Pelicci, P. G. (1996) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4266-6_20 · Cited by 1
Laczika, K. F., Mitterbauer, G., Weltermann, A., et al. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009148411 · Cited by 1
Marini, G., Caccia, S., Guiso, G., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059296 · Cited by 1
Prognosis and therapy of myelodysplastic syndromes
Estey, E. H. (1993) · Cancer treatment and research · doi:10.1007/978-1-4615-3086-2_12 · Cited by 1
Retinoids in the Management of Central Nervous System (CNS) Tumors
Westarp, M. E. (1997) · Advances in organ biology · doi:10.1016/s1569-2590(08)60059-2
Arsenic Trioxide in Untreated APL
Estey, E. H. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_24
Effects of Natural and Synthetic Retinoids on the Differentiation and Growth of Squamous Cancers
Kadara, H. N., & Lotan, R. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7203-3_13
Re: Response of Aleukemic Granulocytic Sarcoma to All-trans-retinoic Acid Plus Interferon Alfa-2a
Fleming, G. F., Waggoner, S. E., Wu, S. J., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.172-a
Tretinoin overdose: A first case report
Su-Yin, A. N., Wong, J. A., Wiegand, T. J., et al. (2009) · Journal of Medical Toxicology · doi:10.1007/bf03161091
Direct evidence of altered bone metabolism caused by all-trans retinoic acid
Nagasaka, S., Aoyagi, A., Mori, S.-I., et al. (1995) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf01771325
Metadata
- Authors
- Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1992-01-15
- Volume
- 79
- Issue
- 2
- Pages
- 299-303
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4246713397
- Cited by
- 314
- References
- 0
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 6 · 2015: 12 · 2014: 9 · 2012: 7
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- all-trans retinoic acid, acute promyelocytic leukemia, relapse, drug resistance, plasma drug concentration, pharmacokinetics, leukemia cell differentiation, dose escalation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
